Efficacy variables included mean percentage changes in LDL-C , HDL-C , non-HDL-C , and apolipoprotein B ( ApoB ) , and median percentage changes in TG and high-sensitivity C-reactive protein ( hsCRP ) from baseline ( i.e. start of the open-label extension after 12 weeks of treatment with rosuvastatin 10 mg + fenofibric acid 135 mg ) to incremental time points up to 52 weeks in the extension study , and the proportion of patients achieving individual and combined goals for LDL-C and non-HDL-C .
